Cargando…
Sex-specific disease outcomes of HIV-positive and HIV-negative drug users admitted to an opioid substitution therapy program in Spain: a cohort study
BACKGROUND: Opioid substitution therapy has improved the survival of heroin users with and without HIV infection. We aimed to analyze sex differences in mortality rates and predictors of death among those admitted to a methadone treatment program (MTP). METHODS: Longitudinal study of patients enroll...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4261781/ https://www.ncbi.nlm.nih.gov/pubmed/25231321 http://dx.doi.org/10.1186/1471-2334-14-504 |
_version_ | 1782348327282540544 |
---|---|
author | Muga, Roberto Rivas, Inmaculada Faure, Eva Fuster, Daniel Zuluaga, Paola Rubio, Manuela Muñoz, Trinidad Torrens, Marta Tor, Jordi Sanvisens, Arantza |
author_facet | Muga, Roberto Rivas, Inmaculada Faure, Eva Fuster, Daniel Zuluaga, Paola Rubio, Manuela Muñoz, Trinidad Torrens, Marta Tor, Jordi Sanvisens, Arantza |
author_sort | Muga, Roberto |
collection | PubMed |
description | BACKGROUND: Opioid substitution therapy has improved the survival of heroin users with and without HIV infection. We aimed to analyze sex differences in mortality rates and predictors of death among those admitted to a methadone treatment program (MTP). METHODS: Longitudinal study of patients enrolled in a MTP from 1992 to 2010. Socio-demographic and drug use characteristics, and markers of viral infections were assessed at entry. Vital status was ascertained by clinical charts and the mortality register. Four calendar periods were defined according to the introduction of preventive and treatment interventions in Spain. Predictors of death were analyzed by Cox regression models. RESULTS: 1,678 patients (82.8% men) were included; age at first heroin use was 18.6 years (IQR: 16–23 years), and age at first entry into a MTP was 30.7 years (IQR: 26–36 years). A total of 441 (26.3%) deaths occurred during 15,124 person-years (p-y) of follow-up (median: 9.2 years, IQR: 4–13 years). HIV infection was the main predictor of death in men (HR = 3.5, 95% CI: 2.1-5.7) and women (HR = 3.2, 95% CI: 1.2-8.7 ) and main cause of death was HIV/AIDS. Overall mortality rate was 2.9 per 100 p-y (95% CI: 2.7-3.2 per 100 p-y) and death rates decreased over time: 7.4 per 100 p-y (95% CI: 6.3-8.8 per 100 p-y) for the 1992–1996 period to 1.9 per 100 p-y (95% CI: 1.6-2.4 per 100 p-y) for the 2007–2010 period. In women, a slightly increase in mortality was observed in recent periods specifically among HIV-positive women (3.7 per 100 p-y in period 2002–2006 and 4.5 per 100 p-y in 2007–2010). CONCLUSIONS: Significant reductions in mortality of patients in MTP are observed after nineteen years of observation. However, HIV infection shows a great impact on survival, particularly among HIV-infected women. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1471-2334-14-504) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4261781 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-42617812014-12-10 Sex-specific disease outcomes of HIV-positive and HIV-negative drug users admitted to an opioid substitution therapy program in Spain: a cohort study Muga, Roberto Rivas, Inmaculada Faure, Eva Fuster, Daniel Zuluaga, Paola Rubio, Manuela Muñoz, Trinidad Torrens, Marta Tor, Jordi Sanvisens, Arantza BMC Infect Dis Research Article BACKGROUND: Opioid substitution therapy has improved the survival of heroin users with and without HIV infection. We aimed to analyze sex differences in mortality rates and predictors of death among those admitted to a methadone treatment program (MTP). METHODS: Longitudinal study of patients enrolled in a MTP from 1992 to 2010. Socio-demographic and drug use characteristics, and markers of viral infections were assessed at entry. Vital status was ascertained by clinical charts and the mortality register. Four calendar periods were defined according to the introduction of preventive and treatment interventions in Spain. Predictors of death were analyzed by Cox regression models. RESULTS: 1,678 patients (82.8% men) were included; age at first heroin use was 18.6 years (IQR: 16–23 years), and age at first entry into a MTP was 30.7 years (IQR: 26–36 years). A total of 441 (26.3%) deaths occurred during 15,124 person-years (p-y) of follow-up (median: 9.2 years, IQR: 4–13 years). HIV infection was the main predictor of death in men (HR = 3.5, 95% CI: 2.1-5.7) and women (HR = 3.2, 95% CI: 1.2-8.7 ) and main cause of death was HIV/AIDS. Overall mortality rate was 2.9 per 100 p-y (95% CI: 2.7-3.2 per 100 p-y) and death rates decreased over time: 7.4 per 100 p-y (95% CI: 6.3-8.8 per 100 p-y) for the 1992–1996 period to 1.9 per 100 p-y (95% CI: 1.6-2.4 per 100 p-y) for the 2007–2010 period. In women, a slightly increase in mortality was observed in recent periods specifically among HIV-positive women (3.7 per 100 p-y in period 2002–2006 and 4.5 per 100 p-y in 2007–2010). CONCLUSIONS: Significant reductions in mortality of patients in MTP are observed after nineteen years of observation. However, HIV infection shows a great impact on survival, particularly among HIV-infected women. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1471-2334-14-504) contains supplementary material, which is available to authorized users. BioMed Central 2014-09-17 /pmc/articles/PMC4261781/ /pubmed/25231321 http://dx.doi.org/10.1186/1471-2334-14-504 Text en © Muga et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Muga, Roberto Rivas, Inmaculada Faure, Eva Fuster, Daniel Zuluaga, Paola Rubio, Manuela Muñoz, Trinidad Torrens, Marta Tor, Jordi Sanvisens, Arantza Sex-specific disease outcomes of HIV-positive and HIV-negative drug users admitted to an opioid substitution therapy program in Spain: a cohort study |
title | Sex-specific disease outcomes of HIV-positive and HIV-negative drug users admitted to an opioid substitution therapy program in Spain: a cohort study |
title_full | Sex-specific disease outcomes of HIV-positive and HIV-negative drug users admitted to an opioid substitution therapy program in Spain: a cohort study |
title_fullStr | Sex-specific disease outcomes of HIV-positive and HIV-negative drug users admitted to an opioid substitution therapy program in Spain: a cohort study |
title_full_unstemmed | Sex-specific disease outcomes of HIV-positive and HIV-negative drug users admitted to an opioid substitution therapy program in Spain: a cohort study |
title_short | Sex-specific disease outcomes of HIV-positive and HIV-negative drug users admitted to an opioid substitution therapy program in Spain: a cohort study |
title_sort | sex-specific disease outcomes of hiv-positive and hiv-negative drug users admitted to an opioid substitution therapy program in spain: a cohort study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4261781/ https://www.ncbi.nlm.nih.gov/pubmed/25231321 http://dx.doi.org/10.1186/1471-2334-14-504 |
work_keys_str_mv | AT mugaroberto sexspecificdiseaseoutcomesofhivpositiveandhivnegativedrugusersadmittedtoanopioidsubstitutiontherapyprograminspainacohortstudy AT rivasinmaculada sexspecificdiseaseoutcomesofhivpositiveandhivnegativedrugusersadmittedtoanopioidsubstitutiontherapyprograminspainacohortstudy AT faureeva sexspecificdiseaseoutcomesofhivpositiveandhivnegativedrugusersadmittedtoanopioidsubstitutiontherapyprograminspainacohortstudy AT fusterdaniel sexspecificdiseaseoutcomesofhivpositiveandhivnegativedrugusersadmittedtoanopioidsubstitutiontherapyprograminspainacohortstudy AT zuluagapaola sexspecificdiseaseoutcomesofhivpositiveandhivnegativedrugusersadmittedtoanopioidsubstitutiontherapyprograminspainacohortstudy AT rubiomanuela sexspecificdiseaseoutcomesofhivpositiveandhivnegativedrugusersadmittedtoanopioidsubstitutiontherapyprograminspainacohortstudy AT munoztrinidad sexspecificdiseaseoutcomesofhivpositiveandhivnegativedrugusersadmittedtoanopioidsubstitutiontherapyprograminspainacohortstudy AT torrensmarta sexspecificdiseaseoutcomesofhivpositiveandhivnegativedrugusersadmittedtoanopioidsubstitutiontherapyprograminspainacohortstudy AT torjordi sexspecificdiseaseoutcomesofhivpositiveandhivnegativedrugusersadmittedtoanopioidsubstitutiontherapyprograminspainacohortstudy AT sanvisensarantza sexspecificdiseaseoutcomesofhivpositiveandhivnegativedrugusersadmittedtoanopioidsubstitutiontherapyprograminspainacohortstudy |